SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (708)11/24/1999 11:52:00 AM
From: Charles Broderick  Respond to of 798
 
Anyone here who fancied that the fastrack application for stents made recently to FDA and due friday, would lead
to renewed bidding between JNJ, Boston and Abbott, will be
pleased by todays BUY from Saloman Barney UK
Quote:UK-Invest
OT: With the Saloman Barney BUY reccommendation
this morning for BCTBF-Biocompatibles...BII.L
are we going to see a reopened contest between
Abbott, JNJ, and Boston for the stents, since the
fasttrack FDA is due Friday???
Source:UK-Invest
Biocompatibles is a buy
Biocompatibles has announced
a link-up with Abbott
Labs to distribute its
BiodivYsio PC coated coronary
stent into the US. As part of
the link-up, Abbott has
invested œ9.5m in a
convertible bond into
Biocompatibles shares.
Merrill believes Abbott to be
an excellent partner for
Biocompatibles; Abbott has
established a leading
position in the arterial device
market.



To: Lighthouse who wrote (708)2/16/2000 2:26:00 PM
From: Lighthouse  Read Replies (1) | Respond to of 798
 
To Anyone:

The snowman continues to melt in the sun. Tobin would like to hit $1.10 for year 2000. How hot will it get the rest of the year?

Stent market share down to mid teen's level. Yuk. Product approvals from the FDA on BSX/Medinol stents has been awful. New realignment of divisions and heads of divisions in aimed at healing this obvious wound. We will see.

Pre-Tobin this company was wildly out of control. I underestimated how bad it was. Shame on me.

Cheers,



To: Lighthouse who wrote (708)2/17/2000 11:18:00 AM
From: Liatris Spicata  Read Replies (2) | Respond to of 798
 
Lighthouse-

Allow me to applaud the quality of your posts.

As to your taxing question. Value Line (10 Dec. '99) projects a constant tax rate of 34% from 1999 to 2004. They also expect new stents this year to increase market share, and believe the value of the franchise remains intact and that the stock offers healthy recovery potential (it was 21 when they reviewed it). They rated it's Timeliness and Safety at 3.

Regards,

Larry


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News